Transmyocardial Laser Therapy: A Strategic Approach
Background: Coronary artery bypass and percutaneous intervention have become the established methods of coronary revascularization in treating angina pectoris. Subsets of angina patients, however, are not amenable to either of these procedures. Transmyocardial laser revascularization (TMR) has been developed as a potential treatment to address such patients, and clinical research to date illustrates the success of TMR for this patient group.
Strategic Plan Summary: Although the symptoms of ischemic heart disease manifest themselves in a variety of ways, the best results with TMR are seen in patients with severe angina rather than in patients with silent ischemia or congestive heart failure. Potential TMR patients receive diagnostic tests to determine if and where the therapy should be applied. A recent cardiac catheterization is required to document the status of and the coronary-system suitability for the planned intervention. It is not appropriate to assume that a patient with nonbypassable, noninterventional coronary artery disease has to be relegated to medical therapy only. Additionally, echocardiography demonstrates the status of cardiac valves and segmental wall motion activity. This knowledge allows the surgeon to determine the sequence of surgery and if abnormalities are present. Once the decision to use TMR use has been made, there are 2 approaches--sole therapy or adjunctive therapy. TMR is not to be substituted for a feasible bypass graft, but the best time to make this decision may well be during the surgery itself, because grafts that appear surgically feasible on an angiogram may be less feasible after the chest has been opened. The decision to perform sole-therapy TMR in the absence of bypassable vessels clearly must be made before opening the chest. Whether to use cardiopulmonary bypass (CPB) and the sequence in which to perform TMR and bypass grafts are based on surgeon preference. The advantage of performing TMR on CPB is that channels can quickly be lased without pause. A potential advantage of performing TMR before bypass grafts is that "channel leak" (bleeding) can be minimized by the conclusion of the surgery. Complete revascularization has become technically more difficult because of the increasing use of percutaneous approaches and because patients are being referred for coronary artery bypass grafting much later in the course of their coronary disease progression than before. TMR may well be a viable alternative to bypassing a heavily diseased, previously intervened, small-diameter coronary artery. Thus, a model in which myocardial perfusion is considered within the context of the natural circulation can be conceived as an alternative to a model in which circulation is altered by interventional, surgical, and/or transmyocardial methods. TMR has been shown to be effective in accomplishing a complete revascularization when the restoration of circulation to ischemic territories with interventional therapy, bypass surgery, or a combination of both has been ineffective. We recommend that interested users follow this "complete revascularization strategy" algorithm for all ischemic vessels being considered for interventional or surgical treatment. Running each diseased vessel through this thought process will ensure that available treatment options are considered in the optimization of a patient's outcome.
Conclusion: The use of TMR for angina relief has evolved into a clinically proven technology that has enabled physicians to address difficult revascularization cases with a therapy that is safe and effective.
Cooley DA, Frazier OH, Kadipasaoglu KA, et al. 1996. Transmyocardial laser revascularization: clinical experience with twelve-month follow-up. J Thorac Cardiovasc Surg 111:791-7.nCosgrove DM, Loop FD, Lytle BW, et al. 1986. Predictors of reoperation after myocardial revascularization. J Thorac Cardiovasc Surg 92:811-21.nFrazier OH, March RJ, Horvath KA. 1999. Transmyocardial revascularization with a carbon dioxide laser in patients with end-stage coronary artery disease. N Engl J Med 341:1021-8.nHorvath KA, Aranki SF, Cohn LH, et al. 2001. Sustained angina relief 5 years after transmyocardial laser revascularization with a CO laser. Circulation 104(suppl 1):I81-4.nHorvath KA, Cohn LH, Cooley DA, et al. 1997. Transmyocardial laser revascularization: results of a multicenter trial with transmyocardial laser revascularization used as sole therapy for end-stage coronary artery disease. J Thorac Cardiovasc Surg 113:645-53.nHorvath KA, Mannting F, Cummings N, Sherman SK, Cohn LH. 1996. Transmyocardial laser revascularization: operative techniques and clinical results at two years. J Thorac Cardiovasc Surg 111:1047-53.nHughes GC, Annex BH, Yin B, et al. 1999. Transmyocardial laser revascularization limits in vivo adenoviral-mediated gene transfer in porcine myocardium. Cardiovasc Res 44:81-90.nHughes GC, Kypson AP, Annex BH, et al. 2000. Induction of angiogenesis after TMR: a comparison of holmium:YAG, CO, and excimer lasers. Ann Thorac Surg 70:504-9.nKohmoto T, DeRosa CM, Yamamoto N, et al. 1998. Evidence of vascular growth associated with laser treatment of normal canine myocardium. Ann Thorac Surg 65:1360-7.nMinisi AJ, Topaz O, Quinn MS, Mohanty LB. 2001. Cardiac nociceptive reflexes after transmyocardial laser revascularization: implications for the neural hypothesis of angina relief. J Thorac Cardiovasc Surg 122:712-9.nMirhoseini M, Shelgikar S, Cayton MM. 1988. New concepts in revascularization of the myocardium. Ann Thorac Surg 45:415-20.nMukherjee D, Bhatt DL, Roe MT, Patel V, Ellis SG. 1999. Direct myocardial revascularization and angiogenesis: how many patients might be eligible? Am J Cardiol 84:598-600.nAllen KB, Dowling RD, DelRossi AJ, et al. 2000. Transmyocardial laser revascularization combined with coronary artery bypass grafting: a multi-center, blinded, prospective, randomized, controlled trial. J Thorac Cardiovasc Surg 119:540-9.nAllen KB, Dowling RD, Fudge TL, et al. 1999. Comparison of transmyocardial revascularization with medical therapy in patients with refractory angina. N Engl J Med 341:1029-36.nArora RC, Hirsch GM, Hirsch K, Armour JA. 2001. Transmyocardial laser revascularization remodels the intrinsic cardiac nervous system in a chronic setting. Circulation 104(suppl 1):I115-20.nBridger CR, Horvath KA, Nugent WC, et al. 2003. Transmyocardial laser revascularization: a report from the Society of Thoracic Surgeons workforce on evidence-based medicine. STS Web site. Available at http://www.sts.org/doc/8228. Accessed December 3, 2003.nBurkhoff D, Schmidt S, Schulman SP, et al. 1999. Transmyocardial laser revascularisation compared with continued medical therapy for treatment of refractory angina pectoris: a prospective randomised trial. ATLANTIC Investigators. Angina Treatments-Lasers and Normal Therapies in Comparison. Lancet 354:885-90.nMukherjee D, Comella K, Bhatt DL, Roe MT, Patel V, Ellis SG. 2001. Clinical outcome of a cohort of patients eligible for therapeutic angiogenesis or transmyocardial revascularization. Am Heart J 142:72-4.nMyers J, Oesterle SN, Jones J, Burkhoff D. 2002. Do transmyocardial and percutaneous laser revascularization induce silent ischemia? An assessment by exercise testing. Am Heart J 143:1052-7.nPeterson ED, Kaul P, Kaczmarek RG, et al. 2003. From controlled trials to clinical practice: monitoring transmyocardial revascularization use and outcomes. J Am Coll Cardiol 42:1611-6.nWehberg KE, Julian JS, Todd JC 3rd, Ogburn N, Klopp E, Buchness M. 2003. Improved patient outcomes when transmyocardial revascularization is used as adjunctive revascularization. Heart Surg Forum 6:328-30.nYamamoto N, Kohmoto T, Gu A, DeRosa C, Smith CR, Burkhoff D. 1998. Angiogenesis is enhanced in ischemic canine myocardium by transmyocardial laser revascularization. J Am Coll Cardiol 31:1426-33.n
How to Cite
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).